drugset / Trial / NCT02028312
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
RandomizedParallel-groupSingle-blindTreatment
Summary
A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel 0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in subjects with dry eye.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-02
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Loteprednol Etabonate | Other / unclassified | 0.5 % | Other |
| Comparator | Cyclosporine | Peptide | 0.05 % | Other |